On January 17, the second round of national collective procurement list was announced, zhejiang Haizheng Pharmaceutical Co., LTD. 's solina succinate new film (Duzheng Biological completed drug evaluation) won the bid with the second good result.
Solina succinate is a product for the treatment of urinary incontinence and/or frequent urination and urgency in patients with overactive bladder. It is the best-selling OAB treatment drug in the world at present. The BE study was completed by Duzheng Biology (clinical research undertaken by the third Xiangya Affiliated Hospital of Central South University, a strategic cooperative unit), and was approved on July 12, 2019, ranking third in China. This is also duzheng Bio once again to help partners successfully catch up with the fast track of consistency evaluation!